A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725
This study is recruiting at 19 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity or Overweight
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Research Site · Dothan, AL
California · 1
- Research Site · Escondido, CA
Florida · 1
- Research Site · Clearwater, FL
Georgia · 1
- Research Site · Stockbridge, GA
Illinois · 2
- Research Site · Champaign, IL
- Research Site · Chicago, IL
Iowa · 1
- Research Site · Ames, IA
Missouri · 1
- Research Site · Kansas City, MO
North Carolina · 2
- Research Site · Rocky Mount, NC
- Research Site · Statesville, NC
North Dakota · 1
- Research Site · Fargo, ND
Ohio · 1
- Research Site · Columbus, OH
Oklahoma · 1
- Research Site · Tulsa, OK
Pennsylvania · 2
- Research Site · Philadelphia, PA
- Research Site · Smithfield, PA
Tennessee · 1
- Research Site · Kingsport, TN
Texas · 3
- Research Site · Houston, TX
- Research Site · Sugar Land, TX
- Research Site · Waco, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.